Affiliation:
1. Zentrum der Inneren Medizin, Medizinische Klinik 1, Klinikum der J. W. Goethe-Universität, Frankfurt am Main, Germany
2. Institut für Virologie, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany
3. Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany
Abstract
ABSTRACT
Hepatitis C virus (HCV) RNA detection and quantification are the key diagnostic tools for the management of hepatitis C. Commercially available HCV RNA assays are calibrated to the HCV genotype 1 (gt1)-based WHO standard. Significant differences between assays have been reported. However, it is unknown which assay matches the WHO standard best, and little is known about the sensitivity and linear quantification of the assays for non-gt1 specimens. Two real-time reverse transcriptase PCR-based assays (RealTime HCV and Cobas Ampliprep/Cobas TaqMan HCV [CAP/CTM]) and one signal amplification-based assay (the Versant HCV RNA, version 3.0, branched DNA [bDNA] assay) were compared for their abilities to quantify HCV RNA in clinical specimens (
n
= 65) harboring HCV isolates of gt1 to g5. The mean differences in the amounts detected by RealTime HCV in comparison to those detected by the bDNA assay and CAP/CTM were −0.02 and 0.72 log
10
IU/ml HCV RNA, respectively, for gt1; −0.22 and 0.03 log
10
IU/ml HCV RNA, respectively, for gt2; −0.27 and −0.22 log
10
IU/ml HCV RNA, respectively, for gt3; −0.19 and −1.27 log
10
IU/ml HCV RNA, respectively, for gt4; and −0.03 and 0.09 log
10
IU/ml HCV RNA, respectively, for gt5. The lower limits of detection for RealTime HCV and CAP/CTM were 16.8 and 10.3 IU/ml, respectively, for the WHO standard and in the range of 4.7 to 9.0 and 3.4 to 44.4 IU/ml, respectively, for clinical specimens harboring gt1 to gt6. Direct comparison of the two assays with samples of the WHO standard (code 96/798) with high titers yielded slightly smaller amounts by RealTime HCV (−0.2 log
10
at 1,500 IU/ml and −0.3 log
10
at 25,000 IU/ml) and larger amounts by CAP/CTM (0.3 log
10
at 1,500 IU/ml and 0.2 log
10
at 25,000 IU/ml). Finally, all three tests were linear between 4.0 × 10
3
and 1.0 × 10
6
IU/ml (correlation coefficient, ≥0.99). In conclusion, the real-time PCR based assays sensitively detected all genotypes and showed comparable linearities for the quantification of HCV RNA, with the exception of gt1 and gt4. The previously reported differences in the absolute quantification of samples harboring gt1 were confirmed and may be explained by different calibrations to the WHO standard.
Publisher
American Society for Microbiology
Reference30 articles.
1. Subtyping of hepatitis C virus isolates by a line probe assay using hybridization
2. Berg, T., V. Weich, G. Teuber, H. Klinker, B. Moeller, J. Rasenack, H. Hinrichsen, T. Gerlach, U. Spengler, P. Buggisch, H. Balk, M. Zankel, C. Sarrazin, S. Zeuzem, et al. 2007. Time to HCV RNA negativation in hepatitis C virus (HCV) type 1-infection during PEG-interferon-alpha-2B plus ribavirin therapy. Differences in relation to the assay sensitivity. Hepatology46:360A.
3. Bland, J. M., and D. G. Altman. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lanceti:307-310.
4. Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV Assay
5. Multilaboratory Comparison of Hepatitis C Virus Viral Load Assays
Cited by
96 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献